The effects of long‐term growth hormone and insulin‐like growth factor‐1 exposure on the development of cardiovascular, cerebrovascular and metabolic co‐morbidities in treated patients with acromegaly

Background  Acromegaly is characterized by the hypersecretion of growth hormone (GH) and insulin‐like growth factor‐1 (IGF‐1). This leads to an increased cardiovascular, cerebrovascular and metabolic morbidity resulting in excess mortality. There is controversy over which biomarker, GH or IGF‐1, better predicts this increased morbidity and mortality. The relationship between the cumulative exposure to GH and IGF‐1 with co‐morbidities in acromegaly has not previously been reported.

[1]  S. Moebus,et al.  Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. , 2010, The Journal of clinical endocrinology and metabolism.

[2]  P. Chanson,et al.  A consensus on criteria for cure of acromegaly. , 2010, The Journal of clinical endocrinology and metabolism.

[3]  S. Radovick,et al.  Targeted deletion of somatotroph insulin-like growth factor-I signaling in a cell-specific knockout mouse model. , 2010, Molecular endocrinology.

[4]  A. Colao.  The GH–IGF‐I axis and the cardiovascular system: clinical implications , 2008, Clinical endocrinology.

[5]  B. Velkeniers,et al.  Divergence between growth hormone and insulin-like growth factor-i concentrations in the follow-up of acromegaly. , 2008, The Journal of clinical endocrinology and metabolism.

[6]  I. Holdaway.  Excess Mortality in Acromegaly , 2007, Hormone Research in Paediatrics.

[7]  G. Romanello,et al.  Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography. , 2006, The Journal of clinical endocrinology and metabolism.

[8]  L. Niskanen,et al.  A nationwide survey of mortality in acromegaly. , 2005, The Journal of clinical endocrinology and metabolism.

[9]  J. Puder,et al.  Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. , 2005, The Journal of clinical endocrinology and metabolism.

[10]  V. Mendoza,et al.  Clinical-Biochemical Correlations in Acromegaly at Diagnosis and the Real Prevalence of Biochemically Discordant Disease , 2004, Hormone Research in Paediatrics.

[11]  G. Gamble,et al.  Factors influencing mortality in acromegaly. , 2004, The Journal of clinical endocrinology and metabolism.

[12]  J. Hardy,et al.  Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly. , 2004, The Journal of clinical endocrinology and metabolism.

[13]  P. Marzullo,et al.  Systemic complications of acromegaly: epidemiology, pathogenesis, and management. , 2004, Endocrine reviews.

[14]  M. Bondanelli,et al.  Pathogenesis and Prevalence of Hypertension in Acromegaly , 2001, Pituitary.

[15]  D. Bonaduce,et al.  Cardiovascular consequences of early-onset growth hormone excess. , 2002, The Journal of clinical endocrinology and metabolism.

[16]  Y. Saitoh,et al.  Characterization of premature atherosclerosis of carotid arteries in acromegalic patients , 2001, Clinical endocrinology.

[17]  M. Salvatore,et al.  Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. , 2001, The Journal of clinical endocrinology and metabolism.

[18]  P. Marzullo,et al.  Increased arterial intima‐media thickness by B‐M mode echodoppler ultrasonography in acromegaly , 2001, Clinical endocrinology.

[19]  N. Sicolo,et al.  Relationship between blood pressure and glucose tolerance in acromegaly , 2001, Clinical endocrinology.

[20]  R. McNally,et al.  Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study , 1998 .

[21]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[22]  S. Orme,et al.  Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. , 1998, The Journal of clinical endocrinology and metabolism.

[23]  Y. Iwamoto,et al.  Assessment of insulin resistance in acromegaly associated with diabetes mellitus before and after transsphenoidal adenomectomy. , 1997, Endocrine journal.

[24]  M. Hanefeld,et al.  Long-Term Effect of Octreotide in Acromegaly on Insulin Resistance , 1995, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[25]  M. Shichiri,et al.  Insulinlike Growth Factor‐I Induces Hypertrophy With Enhanced Expression of Muscle Specific Genes in Cultured Rat Cardiomyocytes , 1993, Circulation.

[26]  E. Martino,et al.  [Acromegalic arthropathy]. , 1993, La Clinica terapeutica.

[27]  D. Chisholm,et al.  Impact of octreotide, a long‐acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly , 1992, Clinical endocrinology.

[28]  R. Alexander,et al.  Regulation of Insulin-like Growth Factor I Messenger RNA Levels in Vascular Smooth Muscle Cells , 1991, Hypertension.

[29]  A Luger,et al.  Decreased peripheral insulin sensitivity in acromegalic patients. , 2009, Experimental and clinical endocrinology.

[30]  M. Shaw,et al.  Basal plasma growth hormone levels in man: new evidence for rhythmicity of growth hormone secretion. , 1990, The Journal of clinical endocrinology and metabolism.

[31]  J. Lie,et al.  Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. , 1980, American heart journal.

[32]  E. Tsalikian,et al.  Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin. , 1976, The Journal of clinical investigation.

[33]  O. Isaksson,et al.  Effects of growth hormone on amino acid transport and protein synthesis in the isolated working rat heart. , 1969, Acta Physiologica Scandinavica.